

Myrna R Nahas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5680766/publications.pdf>

Version: 2024-02-01

33
papers

367
citations

1040056

9
h-index

839539

18
g-index

33
all docs

33
docs citations

33
times ranked

702
citing authors

#	ARTICLE	IF	CITATIONS
1	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1791-1801.	1.4	130
2	Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. <i>British Journal of Haematology</i> , 2019, 185, 679-690.	2.5	52
3	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <scp>MUC</scp> 1. <i>British Journal of Haematology</i> , 2017, 176, 929-938.	2.5	34
4	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	1.4	30
5	Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. <i>Blood Reviews</i> , 2018, 32, 312-325.	5.7	19
6	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e122-e133.	4.6	19
7	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. <i>Haematologica</i> , 2021, 106, 1330-1342.	3.5	19
8	MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3887-3898.	3.6	12
9	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2304-2314.	4.1	10
10	Generalized Acquired Cutis Laxa Associated with Monoclonal Gammopathy of Dermatological Significance. <i>Case Reports in Dermatological Medicine</i> , 2020, 2020, 1-10.	0.3	6
11	A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). <i>Blood</i> , 2021, 138, 3543-3543.	1.4	5
12	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies.. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S42-S43.	2.0	4
13	Challenges in vaccine therapy in hematological malignancies and strategies to overcome them. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1093-1104.	3.1	3
14	Treatment of Multiple Myeloma With Daratumumab in a Kidney Transplant Patient. <i>American Journal of Therapeutics</i> , 2021, 28, e488-e491.	0.9	3
15	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019, 134, 2015-2015.	1.4	3
16	Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia. <i>Acta Haematologica</i> , 2019, 141, 222-224.	1.4	2
17	Transfusion Reactions: A Case Study of an Ocular Adverse Event During Autologous Transplantation. <i>Clinical Journal of Oncology Nursing</i> , 2019, 23, 509-513.	0.6	2
18	A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. <i>Blood</i> , 2018, 132, 1446-1446.	1.4	2

#	ARTICLE	IF	CITATIONS
19	CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model. Blood, 2019, 134, 1386-1386.	1.4	2
20	Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. Blood, 2019, 134, 392-392.	1.4	2
21	T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy. Blood, 2019, 134, 2673-2673.	1.4	2
22	Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2016, 128, 387-387.	1.4	2
23	Posttransplant Lymphoproliferative Disorder Isolated to the Adrenal Gland in a Liver Transplant Patient. ACG Case Reports Journal, 2018, 5, e10.	0.4	1
24	Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy. Blood, 2018, 132, 2728-2728.	1.4	1
25	MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs. Blood, 2016, 128, 2871-2871.	1.4	1
26	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. Blood, 2019, 134, 3227-3227.	1.4	1
27	Transcriptome Profiling of Immune Response to Dendritic/AML Fusion Vaccine. Biology of Blood and Marrow Transplantation, 2020, 26, S13-S14.	2.0	0
28	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Blood, 2016, 128, 4175-4175.	1.4	0
29	Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells. Blood, 2016, 128, 703-703.	1.4	0
30	A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma. Blood, 2016, 128, 4484-4484.	1.4	0
31	Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. Blood, 2019, 134, 3832-3832.	1.4	0
32	Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia. Blood, 2021, 138, 904-904.	1.4	0
33	Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms. Blood, 2021, 138, 2833-2833.	1.4	0